North Capital, Inc. Amylyx Pharmaceuticals, Inc. Transaction History
North Capital, Inc.
- $106 Billion
- Q1 2025
A detailed history of North Capital, Inc. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, North Capital, Inc. holds 500 shares of AMLX stock, worth $2,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$2,450% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AMLX
# of Institutions
144Shares Held
48.9MCall Options Held
281KPut Options Held
438K-
Perceptive Advisors LLC New York, NY6.77MShares$33.2 Million0.85% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$22.8 Million2.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.69MShares$13.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$13.1 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.43MShares$11.9 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $287M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...